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A problem with cancer treatment is that many cancers develop resistance to
chemotherapeutic agents, causing them to fail to accumulate in resistant cancer cells long enough
to have any effect. This is due to the overexpression of a plasma membrane protein called Pglycoprotein (P-gp). Generally, the role of P-gp is to protect the cells from any toxins or foreign
substances by pumping these toxins (including chemotherapeutic drugs) out of the cell. I am
collaborating with the Wise-Vogel laboratory at Southern Methodist University, who utilize a
computer-generated model to predict the structures of P-gp inhibitors that inhibit the action of Pgp. These docking models find drug targets that slow the action of P-gp pumping, as well as help
understand the underlying mechanism of how the protein effluxes toxins from the cell. My current
research is focused on multiple drug analogues that are predicted to inhibit the P-gp protein based
on their docking models. They are tested in cancer cell lines in combination with current
chemotherapeutics to determine efficacy and strength of inhibition so that future chemotherapeutic
drugs can work effectively in cells.
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CHAPTER 1
SYNTHESIS OF P-GLYCOPROTEIN INHIBITOR COMPOUNDS

1.1 Introduction
1.1.1 Cancer
The human body is able to control cell growth and death, but when some cells do not
respond or grow uncontrollably, they can become unrestrained cancerous cells. 1 Chemotherapy is
one of the most common treatments used to kill cancer cells or control their proliferation.2
However, cancers will often develop resistance to chemotherapeutic drugs, mainly due to efflux
of the drug from the cancer cell.3 Furthermore, chemotherapies used to treat the cancer cells in the
body also weaken the patient’s immune system.4 These drawbacks show a need for better therapies
with less side effects.
When cancer cells become immune to several chemotherapeutic drugs that are chemically
and structurally distinct, this is referred to as multi-drug resistance (MDR).5 MDR normally results
in chemotherapy drug failure and, as a result, a bad patient prognosis. Cancer cells can develop
resistance to anticancer drugs by overexpressing one or more ATP-binding cassette (ABC)
transporters, which act as drug efflux pumps.6 Cancer medications are pumped out of cancer cells
before they can do more damage. P-glycoprotein (P-gp, or ABCB1) and Breast Cancer Resistance
Protein (BCRP) are two examples of efflux protein pumps.7

1

1.1.2 Chemotherapy and resistance
Chemotherapy is a type of cancer treatment that exploits chemically synthesized drugs to
inhibit cancer cells from dividing quickly. 8 Different chemotherapeutic agents are developed and
applied depending on cancer type. It is observed that some cancer cells show multidrug resistance
due to the presence of a cell surface efflux pump called P-glycoprotein (P-gp), causing various
treatment complications.9 Each drug works to target the cancer through different pathways and
mechanisms. Thus, many chemotherapy treatments have been devised based on type of cancer and
its pathology.10 Paclitaxel is one example of chemotherapeutics that has a complex structure from
the taxane family isolated from Pacific Yew tree (Taxus brevifolia). This antitumor drug acts by
microtubule inhibition, disruption of cell cycle and division as well as induction of apoptosis. 11
Also, pentostatin is being used to treat leukemia and is commercially available under the name
Nipen. It acts by inhibiting adenosine deaminase and inhibits cancer cell division by damaging
DNA.12 5-Fluorouracil (5-FU) is applied as chemotherapy for several types of cancers such as
colorectal, skin and stomach cancers.13 It actually inhibits an enzyme that slows down DNA
synthesis.14 Anthracyclines, too, are used to treat malignancies. They are a type of antibiotic
extracted from some types of Streptomyces bacteria. Anthracyclines have the capacity to damage
the DNA in cancer cells leading to cell death. 15 These different chemotherapies are usually taken
alone or combined with other drugs to improve the result of killing the cancer cells and controlling
their proliferation.16
Most tumors are quite responsive and highly sensitive to these treatment methods.
However, a growing number of patients exhibit multidrug resistance (MDR) to cancer treatment,
which has thus become a prevalent concern.17 From this predicament stemmed the application of
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a rotation of drugs with other therapies such as radiation or immunotherapy. 18 It is apparent that
new treatments must be developed that incur less side effects and less lethality in healthy cells.
1.1.3 P-glycoprotein
P-glycoprotein (P-gp) is a plasma membrane protein that is responsible for protecting cells
from endogenous toxins.19 P-gp is present in many tissues and helps in detoxifying cells by
pumping xenobiotics across the plasma membrane. P-gp is able to bind and transport a diverse
range of cationic amphipathic molecules ranging in size from 100 to 4000 Da. 20
When the cell undergoes distress from an external drug, the P-gp pumps the toxins out of
the cell to ensure its survival. While this is a useful function in healthy cells, it can lead to multiple
drug resistance in cancer cells. The chemotherapeutic agents are exported out of the tumor before
they exhibit their desired effects.21
P-glycoprotein (P-gp), also known as ABCB1, was the first human ABC transporter
discovered. It is potentially the most researched ABC transporter, especially in relation to MDR.
P-gp, like BCRP, has a diverse substrate set that includes amphipathic, lipid-soluble, and aromatic
compounds.22 Taxanes, anthracyclines, HIV-protease inhibitors, and antibiotics are among the
medications it transports. P-gp is a polypeptide that consists of two nucleotide binding domains.
P-gp has a larger role outside of MDR, which is to protect cells from xenobiotics and toxins. The
protein is present in the mucosal membrane of the bladder, the kidney epithelia, the liver, and the
placenta.23
P-gp is a 170 kDa protein consisting of two pseudosymmetrical halves, each containing
a nucleotide binding domain (NBD) and a transmembrane domain (TMD). 24 Figure 1.1 shows the
crystal structure for P-gp in the “open inward” conformation with NBDs apart and N-terminal half
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of the protein (blue) and the C-terminal half (yellow) are linked by a flexible linker (black dashed
line).25

Figure 1.1 P-gp structure in three dimension. Image adapted from ref 25.

It has been hypothesized that ABC-transporter proteins undergo large conformational
changes powered by the binding and hydrolysis of ATP and that these changes alter the
transmembrane domains from “open to the cytoplasm” (inward-facing) to “open to the
extracellular space” (outward-facing) conformations. To understand the mechanism of P-gp,
Professor J. Wise at Southern Methodist University used a computational model to study and
design synthetic compounds that inhibit P-gp’s efflux pump action by acting as a competitive
inhibitor to its nucleotide bindings domains. 26 Through the application of molecular dynamic
studies, the development of small molecule P-gp inhibitors has made noteworthy progress. Cells
treated with both the P-gp inhibitor and paclitaxel responded with a 2,400-fold increase in
cytotoxicity as compared to a positive control treatment with only paclitaxel. These results give
conclusive evidence that predicted molecules were effective against the efflux pump and lead to
4

inhibition of P-gp in prostate cancer cells, reducing drug export and restoring cell sensitivity to
chemotherapeutics. Using P-gp inhibitors in combination with chemotherapy could be key in
resolving both cost efficiency and efficacy of the treatment, as lower dosages of chemotherapeutics
will be needed to achieve their desired effect.
1.1.4 Computational model of P-glycoprotein
Recent advancements have brought upon exceptional techniques which can be used to aid
drug discovery and development.27 Among these are computational methods which have
contributed greatly in the discovery of Human Immunodeficiency Virus (HIV) medications such
as ritonavir and saquinavir.28 These methods have also been effective in terms of drug screening
to identify and modify particular chemotherapeutics including Luminespib, an experimental
anticancer drug.29 To create highly superior medications, drug screenings often utilize lead
optimization in the process. This technique improves the overall performance of the drug while
reducing its off-target effects.30 To elaborate the process, high yield screenings produce small
molecules as initial hit molecules. These molecules can then be optimized further into lead
molecules, resulting in a drug with better pharmacology properties. Despite the benefits associated
with lead optimization, this method requires a considerable amount of cost to be accomplished.
To address this problem, computational methods are incorporated into lead optimization as well.
Computational lead optimization involves decreasing molecules that require testing and increasing
the proportion of produced leads that possess the necessary features, reducing the overall expense
of the process.27
The diagram below in Scheme 1.1 is comprised of four components: the orange boxes, the
blue boxes, the green boxes and a single yellow box. The orange boxes present the preparation
phase wherein the root and alignment atoms of the scaffolds and precursor fragments are marked.
5

The blue boxes, on the other hand, represent the building phase while the green boxes denote the
docking phase. Lastly, the yellow box signifies the final step wherein the dock results are analyzed
and the observations are applied into lab configurations.31

Scheme 1.1. Step-by-step diagram for ChemGen program. Figure adapted from reference 31.
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Figure 1.2. SMU-29 structure that successfully inhibited P-gp activity.

P-gp is known as a fundamental membrane efflux pump that acts by transferring
compounds such as chemotherapeutic drugs out of the cell. 32 Many studies have been done to
develop the multi-drug resistance by inhibiting expression of P-gp. Dr. Wise and his group
screened molecules for potential inhibition of P-gp activity by using in silico molecular docking
assays. One of these molecules, SMU-29 (Figure 1.2), was found to be a successful inhibitor of
P-gp activity in vitro, resulting in the re-sensitization of cancer cells in culture to
chemotherapeutics.33 Structural variants of SMU-29 were screened in silico to create compounds
that exhibit higher binding affinity to P-gp's nucleotide binding domain (NBD) by using ChemGen
a novel computational medicinal chemistry software designed by Dr. Wise. An estimated binding
affinity was calculated for these compounds when they were docked with multiple models of Pgp. Approximately 500 structural variants of SMU-29 with equivalent or better estimated binding
affinity relative to the SMU-29 compound were designed. Three of these compounds target that
are shown in Figure 1.3 have been synthesized after specific docking experiments and screened
with P-gp in vitro. These analogues share a common pyrazole motif and differ with variations in
the N-chloroacetamide motif. The aim of this project is to synthesize these SMU-29 analogues by
conserving the pyrazole and appending various amines to the structure.
7

Figure 1.3. Chemical structures for three compounds that were screened by Visual Molecular
Dynamics (VMD) group 1.

1.1.5 Docking simulation of SMU-29 variants to P-gp
The docking studies were used to test P-gp inhibitors in silico. Inhibiting P-gp efflux
activity prevents the protein from lowering intracellular concentrations of therapeutics to
subtherapeutic-levels. P-gp can be responsible for MDR against various cancer chemotherapies.
This study aimed to determine binding affinities of the P-gp inhibitors. Using Autodock Vina, and
Visual Molecular Dynamics (VMD), docking simulations of SMU-29 variants to P-glycoprotein
were made. Through these simulations, it was found that the highest-affinity binding location is
near P-gp’s nucleotide binding domain (NBD).

Figure 1.4. The human model of P-gp with SMU-29-231 inhibitor.

8

SMU-29-231 is shown in white, docked SMU-29 to P-gp. Figure 1.4 shows the human
model of P-gp when it docked with SMU-29-231. SMU-29 in the 2hyd_nbd_1 NBD, showing
probablehydrogen-bond interactions.

Figure 1.5. SMU-29 binding to amino acids.

The estimated dissociation constant KD and binding affinity for SMU-29 variants are listed
in Table 1.1. Binding affinities were predicted and compared to original SMU-29. Eight inhibitors
with equivalent or better-estimated binding affinity relative to the original SMU-29 except SMU29-286 and SMU-29-238.
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Table 1.1. Estimated value for KD and binding affinity.
SMU-29 Variants

KD (M)

10

Binding affinity (J/mol)

11

1.2. Results and Discussion
1.2.1 Retrosynthesis
We begin synthesis with the basic concept of using retrosynthesis to provide a roadmap to
obtain the SMU-29 variants. We chose to make a disconnection at the carbon-sulfur bond, leaving
the thiol on the pyrazole motif as shown in Scheme 1.2 below.

Scheme 1.2. Retrosynthesis route for SMU-29 analogues.

The methodology behind this synthetic route is that we can form the pyrazole motif as a
stable synthetic intermediate, thus allowing for facile screening of all analogues by connecting
thiol motif 6 to chloroacetyl motif 7 via nucleophilic substitution. The thiol pyrazole configuration
6 would be formed via hydrolysis of thioacetate 5 after substitution of the chloride in 4 by
potassium thioacetate. The N-chloroacetamide 4 is completed by nucleophilic acyl substitution.
The amino pyrazole 3 would be produced after phenyl diazoacetonitrile 2 is reacted with
phenylhydrazine. The configuration of phenyl diazoacetonitrile can be formed when the aldehyde
reacts with diazoacetonitrile 1. The first step in this approach starts with reacting aminoacetonitrile

12

hydrochloride with NaNO2. The second set of configurations N-chloroacetamide derivatives 7 are
synthesized by reacting amines through acyl substitution with chloroacetyl chloride.

Figure 1.6. Modular synthetic route to access 29 derivatives.

The synthetic route of target inhibitors of P- glycoprotein were devised using this
retrosynthetic route.
1.2.2 Synthesis of the pyrazole 6
The synthesis of pyrazole 6 started with the preparation of diazoacetonitrile 1 using
aminoacetonitrile hydrochloride and sodium nitrite as shown below in Scheme 1.3.
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Scheme 1.3. Synthesis of diazoacetonitrile 1, trimethylphenyl propanenitrile 2, amino-phenyl
pyrazole 3, and alkyl chloride 4.

After that, the diazoacetonitrile 1 was reacted with trimethylbenzaldehyde by using
BF3·OEt2 as a catalyst to synthesize 3-oxo-3-(2,4,5-trimethylphenyl) propanenitrile 2.34 Pyrazole
is a heterocyclic organic compound that has a five-membered ring and two adjacent nitrogen
atoms. This nitrogen made the pyrazole of interest to the chemical industry and pharmaceutical
industry. In addition, many previous studies reported anticancer inhibitors that contain pyrazole
show promising efficacy in different type of cancer. 35 Synthesis of the five-membered ring was
performed under neat conditions; benzoylacetonitrile 2 was reacted with phenylhydrazine to
generate 1-phenyl-pyrazole 3 with a good yield.36 After obtaining the pyrazole, acyl substitution
was done by reacting the pyrazole with chloroacetyl chloride using DCM as a solvent and giving
a 97% yield. The previous reactions are shown in Scheme 1.3. In addition, potassium thioacetate
was used to displace the chloride and give thioacetate 5 in the presence of anhydrous THF as
shown below in Scheme 1.4.37
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Scheme 1.4. Synthetic procedure for compound 5.

1.2.3 Hydrolysis of thioacetate
The last step of the thiol pyrazole intermediate is the hydrolysis of the thioacetate. This
step was attempted in both acidic and basic conditions as it shown in Table 1.2.38 The most
successful procedure was done through hydrolysis of thioacetate in basic conditions of 2M NaOH
and deoxygenated methanol to get the target compound mercapto amino-triphenyl pyrazole 6.

Table 1.2. Overview for acid or base-mediated reactions to hydrolyze thioacetate.
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Table 1.2 shows the optimization to the best condition to hydrolyze the thioacetate. This
compound has two different functional groups, the thioacetate and secondary amide, but hydrolysis
using acid failed to give any product. However, when using basic conditions, the reaction gave
product. Only a low yield occurred when sodium methoxide was used. 39 Sodium hydroxide in
methanol successfully cleaved the thioester groups of compound 5 and gave a high yield up to
70% when degassed with a freeze-thaw method.40
1.2.4 Synthesis of the N-chloroacetamide motifs 7-13
The acyl substitution reaction of various amines was done using chloroacetyl chloride to
form the intermediate of N-chloroacetamide. The activation of different amines was done by using
various

amines

such

as:

2-aminonaphthalene,41

iminodibenzyl,42

3,4,5-

trimethoxybenzylamine,431,3-benzothiazol-6-amine,44 1-adamantylamine,45 benzhydrylamine46
and 4-fluorobenzylamine.47 These reactions were done by reacting the various amines with
chloroacetyl chloride and Et3N to get the products in high yield as shown in Table 1.3.

Table 1.3. Acylation substitution products for variant amine.
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Compound 14 was synthesized by using a Friedel-Crafts acylation with 9-fluorene,
chloroacetylchloride and aluminum chloride as a catalyst. The reaction shown in Scheme 1.5.48

Scheme 1.5. Friedel-Crafts acylation reaction.

1.2.5 Synthesis of final anticancer drugs
After finishing the previous steps, the last step was done by SN2 nucleophilic substitution.
The reaction was done by using the thiol pyrazole motif and acetyl motif as shown in Scheme 1.6,
in the presence of potassium carbonate and deoxygenated DMF. 49 Eight anticancer drugs were
successfully synthesized. Characterization was done using proton and carbon NMR.
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Scheme 1.6. Final steps in synthesis of anticancer drug analogues.

1.2.6 Synthesis of SMU-544 and SMU-551
Synthesis of SMU-544 was done by reacting isatin with hydrazinecarbothioamide to form
aromatic sulfide derivative as is show in Scheme 1.7 below. After that, the sulfide motif 15 was
reacted with acetyl chloride 4 in the presence of triethylamine to form final SMU-541 in 58%.

Scheme 1.7. Synthesis procedure of sulfide derivative and SMU-541.
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The final analogue SMU-551 was done starting from the sulfide motif 17. First was the
formation of 5-bromonicotinoyl chloride 16 by reacting 5-bromonicotinic acid with thionyl
chloride. After that, the carbonyl chloride 16 was reacted with 3-aminothiophenol to form the
sulfide motif 17, 5-bromo-N-(3-mercaptophenyl) nicotinamide, as it shown below in Scheme1.7.
Finally, SMU-551 was successfully synthesized by reacting the sulfide motif 17 with acetyl
chloride 4 by SN2 reaction.

Scheme 1.8. Synthesis procedure of sulfide derivative and SMU-551.
1.3. Cell culture methods
1.3.1 Cell lines and cell culture
The cell culture studies have all been performed in the Vogel – Wise Lab, Department of
Biological Sciences at SMU by Dr. Amila.
For these experiments, multidrug-resistant DU145TXR cells were used that derived from
the human prostate cancer cells DU145. Dr. Evan Keller (University of Michigan, Ann Arbor, MI)
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generously provided both the chemotherapeutic sensitive DU145 human prostate cancer cells
specimens, together with the multidrug resistant sub-line, DU145TXR. The DU145TXR cell lines
were maintained under positive selection pressure by supplementing the complete medium with
10 nM of paclitaxel from Acros Organics, NJ. Both DU145 and DU145TXR cell lines were then
maintained in complete media composed of RPMI1640 with L-glutamine, 10% fetal bovine serum
(FBS; BioWest, Logan, UT), 100 U/mL penicillin, and 100 µg/mL streptomycin and were kept in
a humidified incubator at 37 degrees Celsius with 5% CO2. Dr. Robert Harrod (Southern Methodist
University, Dallas, TX) provided the noncancerous human fetal lung cell line, HFL1. 50 This was
maintained in complete media as well which is composed of F12K with L-glutamine, 10% FBS
(BioWest, Logan, UT), 100 U/mL penicillin, and 100 µg/mL streptomycin in a humidified
incubator at 37 degrees Celsius and 5% CO2 as well. In addition, the HFL1 cells’ growth surfaces
were treated with 0.1 mg/mL rat tail collagen (BD Biosciences, Palo Alto, CA) in 0.02 N acetic
acid for 10 minutes and rinsed with PBS after use to enhance the cells’ attachment properties. All
cell culture materials were retrieved from Corning Inc. (Corning, NY) unless otherwise stated.
1.3.2 Calcein AM assay
Calcein AM, DU145TXR cells were seeded in 96 wells plates and permitted to grow
completely until they reach confluency. This was done to assess the inhibition of P-gp-catalyzed
transport of the P-gp pump substrate. Afterwards, the medium was removed and the cells were
treated without the presence of 2 μM P-gp inhibitory compounds as well as 1 μg/mL calcein AM.
This was then diluted into phenol red free RPMI 1640 media. The effect of pre-incubation of
compound cells were investigated by treating the cells with P-gp inhibitory compounds, incubating
the specimens by 37 degrees Celsius for 6 hours, and adding calcein AM afterwards.
Measurements were done with the following parameters: fluorescence excitation at 485 nm with
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a 20 nm gate emission at 535 nm with a 20 nm gate. The BioTek Cytation 5 imaging multi-mode
reader was used over 60 minutes in 20-minute intervals. The results of the investigations were
plotted as the mean with the standard deviation (SD) of six replicates per concentration. This serves
as representatives of at least two independent experiments as well.
1.3.3 MTT cell viability assay
The cells were initially trypsinized from monolayers and were seeded with 3000 cells in
150 µL of complete medium in a 96 well plate afterwards. After 24 hours, the cells were treated
with paclitaxel retrieved from Acros Organics, NJ for 48 hours. This process is done with or
without the presence of P-gp inhibitor compounds dissolved in DMSO or DMSO controls. 48
hours after the treatment, MTT assays were executed using 5 mg/mL of MTT (Acros Organics,
NJ) solution prepared in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na 2HPO4, 1.8 mM KH2PO4,
and pH 7.4). The media was then removed and the formazan crystals were mixed and dissolved in
100 µL of DMSO 4 hours after incubation with MTT. Using a BioTek Cytation 5 imaging multimode reader (Bio-Tek, Winooski, VT), the absorbance at 570 nm was measured. The DMSO
treated cells were assigned as representatives for 100% viability. With this, percent viability is
calculated using the following formula:
Absorbance at 570 nm of test well
% Viability =
Absorbance at 570 nm of DMSO treated cells
Using MTT and complete medium without cells, background absorbance was quantified.
This was then subtracted from all the test values. Lastly, a four-parameter variable non-linear slope
were utilized in generating the graphical representations and in identifying IC50 values.
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1.4 Cell culture results

Figure 1.7. Optimization of the 29 variants that inhibit the P-gp by reduce the cell viability of
MDR prostate cancer cells in the presence of chemotherapeutic more efficiently compared to
original SMU-29.
The viability of the DU145TXR cells treated with derivatives 238, 255, 278, 280, and 286
with or without 100 nM of paclitaxel is shown in Figure 1.7. Similar to the previous group, the
inhibitory action of these variants can be observed at 3 µM concentrations and higher.
Performance-wise, it can be observed that the Group 2 variations incorporated with paclitaxel were
superior to the original 29-compound. This is the case for all derivates except for 286. This variant,
however, showed high toxicity levels at a concentration of 15 µM. Similarly, variant 280 displayed
signs of toxicity to cancer cells at 3 µM concentrations without the presence of paclitaxel. Another
test was performed to determine the IC50 values necessary for reversing MDR with these
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inhibitors. In this test, the DU145TXR cells were treated with fixed concentrations of inhibitors
while adding varying doses of paclitaxel as seen in Figure 1.8.

Figure 1.8. Compound 29 reverses paclitaxel resistance by rationally designed versions of the
Pgp inhibitor.

1.4.1 Calcein accumulation
The P-gp substrate real-time accumulation in the presence or absence of P-gp inhibitors
was previously evaluated through calcein AM accumulation assays. The process involved the
incubation of P-gp overexpressing DU145TXR cells with the corresponding inhibitors in the
presence of the P-gp substrate. This led to cellular accumulation of calcein-AM and the cleavage
of its acetoxymethyl ester groups, generating the highly fluorescent compound, calcein. The
calcein remains in the cells and its relative fluorescence is observed and measured over time. The
results of these assays are presented in the left panel of Figure 1.9.
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Figure 1.9. Cellular accumulation of the fluorescent dye calcein.

From these records, it can be seen that the cellular accumulation of fluorescent calcein in
cells treated with any of the three Group 1 29 variants were lower than that of the cells treated with
the parental compound. Several variables are presumed to affect the previous results. The lower
accumulation of calcein may be associated with the retention of the compounds in the cellular
membrane due to their increased logP values relative to 29 values. These observations were further
tested using similar calcein accumulation assays performed after a 6-hour pre-incubation with the
29-variants and the parental compound 29. To clarify, the preferential partitioning variants in the
hydrophobic part of the cell membrane would keep them more distant from the putative allosteric
site on P-gp located adjacent to the membrane in the cytoplasm. Once again, the results of these
tests are shown in Figure 1.8. The data indicates that the 6-hour preincubation resulted in a slight
improvement in the calcein accumulation in the presence of variants for all Group 1 compounds.
The same cannot be said for the specimens that did not undergo preincubation. Nevertheless, the
performance of these variants in these assays was still inferior compared to the parental compound
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29. Summarizing, the prostate cancer cell line, DU145TXR, overexpressing P-gp was treated with
calcein AM and 2 µM of the indicated P-gp inhibitors. For comparison, two setups were done, one
with a 6-hour preincubation and the other without.
1.4.2 Comparison between predicted KD and IC50
The correlation between the predicted KD dissociation constant and IC50 value is shown
in Table 1.4.

Table 1.4. Estimated value for predicted KD and measured IC50.
SMU-29 vaiants

KD (M)

IC50
(M)

SMU-29
vaiants
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KD
(M)

IC50
(M)

1.5. Conclusion
Our results give conclusive evidence that the ten analogues we have synthesized against
the efflux pump all effectively lead to inhibition of P-gp in prostate cancer cells. Reducing drug
export and restoring cell sensitivity to the chemotherapeutic drugs. Four P-gp inhibitors, namely
216, 227, 231, and 278, that reversed multidrug resistance in in vitro were produced in this study.
From the four inhibitors, three variants were capable of reversing MDR without being substrates
for P-gp. These inhibitors were variants generated from the original P-gp inhibitor, 29, and all
exhibited greater efficacy in reversing MDR compared to the parental compound. Further research
is recommended to evaluate the inhibitors’ effectiveness in in vivo as this approach shows potential
of saving overall cost and time in identifying drugs both in in vitro and in vivo conditions.
ChemGen was the main platform used in the synthesis involved in this study. A docking
routine was implemented and using MTT assays, it was observed that three Group 1 derivatives
of 29, namely 216, 227, and 231, enabled the P-gp overexpressing prostate cancer cell line,
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DU145TXR, to re-sensitize to paclitaxel, a chemotherapeutic. Given this, the active range of the
concentration of the variants of 29 was analyzed.
Our research could be key to solving issues of cost and side effects since less drug will be
needed to achieve maximum effect. This project shows promising results and that our synthetic
work in the lab has validated the computational model. In addition, the project will be continued
by selecting the top compounds predicted to have high binding affinity, synthesizing it as shown
below in Scheme 1.9, and test it in vitro.

Scheme 1.9. Retrosynthesis future anticancer drug that are predicted by computer.
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1.6 Experimental section
1.6.1 Synthetic procedures
General materials and methods.
The reactions were performed under nitrogen and dried glassware. Reagents were
purchased from Sigma-Aldrich (St. Louis, MO), Alfa Aesar (Ward Hill, MA), EMD Millipore
(Billerica, MA), Oakwood Chemical (West Columbia, SC), and Cayman Chemical (Ann Arbor,
MI). Silica gel P60 (SiliCycle) was used for column chromatography and Analytical
Chromatography TLC Silica gel 60 F254 (Merck Millipore, Darmstadt, Germany) was used for
analytical thin layer chromatography. 1H NMR and 13C NMR spectra were used for analyzed the
compounds by using CDCl3 (Cambridge Isotope Laboratories, Cambridge, MA) on a JEOL 500
MHz and
BRUKER 400 MHz spectrometer in the Department of Chemistry at Southern Methodist
University. Chemical abbreviations are used as follows: CH2Cl2, dichloromethane; EtOAc, ethyl
acetate;

THF,

tetrahydrofuran;

ObenzotriazoleN,N,N’,N’-tetramethyl-

DMF,

dimethylformamide;

uronium-hexafluoro-

H2O,

water;

phosphate;

HBTU,
DIPEA,

N,Ndiisopropylethylamine; KOH, potassium hydroxide; DMSO, dimethylsulfoxide N2, nitrogen.
High resolution mass spectroscopy was performed on a Shimadzu IT-TOF (ESI source) and low
resolution mass spectroscopy was performed on a Shimadzu LCMS-8050 Triple Quadrupole
LCMS (ESI source) or a Shimadzu Matrix Assisted Laser Desorption/Ionization MS (MALDI) at
the Shimadzu Center for Advanced Analytical Chemistry at the University of Texas, Arlington.
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Diazoacetonitrile (2)11 Aminoacetonitrile hydrochloride (0.575 g, 6.21 mmol, 1.0 equiv) was
dissolved in water (10 mL) and CH2Cl2, and then placed in an ice bath. The mixture was stirred
and then sodium nitrite (0.43 g, 6.21 mmol, 1.0 equiv) was added over 5 min. After 15 min, the
reaction mixture was extracted with CH2Cl2, washed with brine, and dried with Na2SO4. The
solution was filtered and used directly in the next step using an estimated yield of 30%.

3-oxo-3-(2,4,5-trimethylphenyl)propanenitrile (3)11 2,4,5-trimethylbenzaldehyde 1 (183 mg,
1.24 mmol, 1.5 equiv) was dissolved in a minimum amount of CH2Cl2 and added to a solution of
diazoacetonitrile 2 (1.9 mmol, 1.0 equiv) in dichloromethane. BF3·OEt2 (0.4 mmol, 0.004 mL, 0.2
equiv) was added dropwise to the reaction mixture until gas stopped evolving and the color was
changed from light green to dark red. After 20 min, the reaction mixture was concentrated and
purification done by silica column chromatography using (1:5 Ethyl Acetate: Hexane) to give a
tan solid (162 mg, 0.86 mmol, 70% yield). 1H NMR (500 MHz, CDCl3) δ 7.36 (s, 1H), 7.06 (s,
1H), 4.02 (s, 2H), 2.50 (s, 3H), 2.28 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 19.4, 20.0,
21.6, 31.3, 114.4, 130.9, 131.3, 134.3, 134.5, 138.4, 143.2, 188.7.

1-phenyl-3-(2,4,5-trimethylphenyl)-1H-pyrazol-5-amine (4) Compound 4 was prepared by
adaptation of a literature procedure.12 Benzoylacetonitrile 3 (250 mg, 1.33 mmol, 1.0 equiv) and
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phenylhydrazine (0.31 mL, 1.3 mmol, 1.0 equiv) were added to pressure tube and heated to 165
°C for six hours. The mixture was purified by silica column chromatography using CH2Cl2 to give
a yellow solid (258 mg, 0.931 mmol, 70% yield). 1H NMR (500 MHz, CDCl3) δ 7.66 (m, 2H),
7.48 (m, 2H), 7.42 (m, 1H), 7.32 (m, 1H), 7.00 (s, 1H), 5.81 (s, 1H), 3.82 (s, 2H), 2.46 (s, 3H),
2.24 (s, 6H); 13C NMR (125 MHz, CDCl 3) δ 18.7, 19.5, 20.4, 91.4, 123.6, 126.9, 129.5, 130.2,
130.5, 132.2, 133.2, 133.5, 135.9, 139.1, 144.6, 152.4; HRMS calcd for C18H19N3 (M+H)+
278.1652, found 278.1650.

2-chloro-N-[1-phenyl-3-(2,4,5-trimethylphenyl)-1H-pyrazol-5-yl]acetamide (5) Pyrazole 4
(530 mg, 1.93 mmol, 1.0 equiv) was dissolved in CH2Cl2 and placed in an ice bath. Chloroacetyl
chloride (260 mg, 2.30 mmol, and 0.22 mL) was added dropwise. The reaction mixture was stirred
overnight at room temperature. The reaction washed with H2O and brine, dried over Na2SO4,
filtered and concentrated. The product was obtained as a brown crystal (660 mg, 1.87 mmol, 97%
yield) and used without any further purification,1H NMR (500 MHz, CDCl3) δ 8.77 (s, 1H), 7.53
(m, 4 H), 7.43 (s, 2H), 7.03 (s, 1H) 6.90 (s, 1H), 4.15 (s, 2H), 2.48 (s, 3H), 2.25 (s, 6H); 13C NMR
(125 MHz, CDCl3) δ 19.3, 19.5, 20.7, 42.7, 98.7, 124.6, 128.7, 129.6, 129.8, 130.2, 132.2, 133.4,
, 133.2, 134.0, 134.5, 136.6, 137.4, 152.8, 162.6, 169.2; HRMS calcd for C20H20N3OCl(M+H)+
354.1368, found 354.1371.
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2-(acetylsulfanyl)-N-[1-phenyl-3-(2,4,5-trimethylphenyl)-1H-pyrazol-5-yl]acetamide

(6)

Chloride 5 (224 mg, 0.640 mmol, 1.0 equiv) was dissolved in 3 mL of anhydrous THF and placed
in an ice bath. KSAc (143 mg, 1.28 mmol) was then added. The reaction was stirred overnight at
room temperature. An orange solid was obtained (243 mg, 0.62 mmol, 97% yield). H NMR (500
MHz, CDCl3) δ 8.38 (s, 1H), 7.51 (m, 4H), 7.42 (m, 2H), 7.08 (s, 1H), 6.85 (s, 1H), 3.59 (s, 2H),
2.48 (s, 3H), 2.32 (s, 6H), 2.25 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 19.3, 19.4, 20.6, 30.2, 33.2,
98.9, 129.8, 133.4, 133.9, 135.4, 136.4, 137.9, 152.4, 165.2, 196.3; HRMS calcd for C22H23N3O2S
(M+H)+ 394.1584, found 394.1576.

2-mercapto-N-(1-phenyl-3-(2,4,5-trimethylphenyl)-1H-pyrazol-5-yl)acetamide (7) In a dry
Schlenk flask, the thioester 6 (80 mg, 0.2 mmol, 1.0 equiv) was dissolved in 3 mL anhydrous
CH3OH and then 0.8 mL of 2 M NaOH (16 mg, 1.6 mmol, 8.0 equiv) was added. The reaction was
degassed using a freeze-pump-thaw procedure. The solvent and reactants in the Schlenk flask were
frozen by submerging in liquid nitrogen. Then, the flask was opened to the vacuum for one minute.
After that, the flask was sealed and allowed to warm up until the solvent has completely become
liquid again. This procedure was repeated two times. After the last cycle was complete, the flask
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was brought to room temperature and filled with N2. After stirring one hour, the reaction mixture
was concentrated and diluted with ethyl acetate, and then acidified to pH = 1 by using HCl. The
extraction was done by using ethyl acetate /water and dried over Na 2SO4. The purification was
done by silica column chromatography using 1:2 (Ethyl Acetate:Hexane) to obtain white crystals
(49 mg, 70% yield). 1H NMR (500 MHz, CDCl3) δ 8.94 (s, 1H),7.52 (m, 4H), 7.40 (m, 2H), 7.00
(s, 1H), 6.90 (s, 1H), 3.36 (s, 2H), 2.47 (s, 6H), 2.24 (s, 3H), 1.8 (s, 1H); 13C NMR (125 MHz,
CDCl3) δ 19.2, 19.7, 21.1, 28.6, 98.1, 124.7, 128.6, 130.0, 130.3, 132.3, 133.3, 133.9, 135.2, 136.4,
138.0, 148.5, 152.7, 165.5; HRMS calcd for C20H21N3OS (M+H)+ 352.1478, found 352.1481.

General procedure for the synthesis of 2-chloro-acetamide derivatives
Each substituted amine (1.0 equiv) was dissolved in 3 mL of anhydrous THF, followed by addition
of one equivalent of Et3N. After placing the reaction mixture in an ice bath, 2-chloroacetyl chloride
(1.2 equiv) was added dropwise for one hour and the reaction was stirred overnight at room
temperature. After being concentrated, CH2Cl2 and water were added and the organic compounds
were extracted three times with CH2Cl2. The organic layers were washed with brine, dried over
Na2SO4, filtered, and concentrated.
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2-chloro-N-(naphthalen-2-yl) acetamide (8)13 Light orange solid (112 mg, 72% yield). 1H NMR
(500 MHz, CDCl3) δ 8.44 (s, 1H), 8.25 (s, 1H), 7.80 (m, 3H), 7.50 (m, 3H), 4.24 (s, 2H).

2-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)ethan-1-one (9).14 White solid (199 mg,
72% yield). 1H NMR (500 MHz, CDCl3) δ 7.45–7.25 (m, 4H), 7.08 (m, 2H), 6.79 (m, 2H), 4.13
(t, 2H, J = 12.6 Hz), 4.02 (t, 2H, J = 12.6 Hz), 3.50 (m, 2H), 3.35 (m, 2H), 3.10 (s, 2H).

2-chloro-N-(3,4,5-trimethoxyphenyl)acetamide (10).15 White solid (212 mg, 75% yield). 1H
NMR (500 MHz, CDCl3) δ 8.24 (s, 1H), 6.81 (s, 2H), 4.14 (s, 2H), 3.79 (s, 9H).
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N-(benzo[d]thiazol-6-yl)-2-chloroacetamide (11).16 White solid (56 mg, 75% yield). 1H NMR
(500 MHz, CDCl3) δ 8.94 (s, 1H), 8.54 (s, 1H), 8.45 (br s, 1H), 8.11 (d, 1H, J = 9.1 Hz), 7.42 (d,
1H, J = 9.1 Hz), 4.23 (s, 1H).

N-((3s,5s,7s)-adamantan-1-yl)-2-chloroacetamide (12).17 White solid (0.97 g, 75% yield). 1H
NMR (500 MHz, CDCl3) δ 6.22 (s, 1H), 3.90 (s, 2H), 1.99 (m, 9H), 1.66 (m, 6H).

N-benzhydryl-2-chloroacetamide (13).18 The mixture was purified by silica column
chromatography using 1:4 Ethyl Acetate:Hexane to give a white solid (0.81 g, 56% yield). 1H
NMR (500 MHz, CDCl3) δ 7.34 (m, 6H), 7.30 (d, 1H, J = 12.6 Hz), 7.24 (m, 4H), 6.25 (d, 1H, J
= 9.2 Hz), 4.12 (s, 2H).

2-chloro-N-(4-fluorobenzyl)acetamide (14).19 White solid (241 mg, 75% yield). 1H NMR (500
MHz, CDCl3) δ 7.24 (m, 2H), 6.98 (m, 2H), 6.88 (s, 1H), 4.40 (s, 2H), 4.06 (s, 2H).
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2-chloro-1-(9H-fluoren-2-yl)ethan-1-one (15).20 9-fluorene (100 mg, 0.6 mmol, 1.0 equiv) was
dissolved in 100 mL of methylene chloride. After the reaction mixture was cooled to 0 °C,
anhydrous aluminum chloride (120 mg, 0.9 mmol, 1.5 equiv) was added. The reaction was stirred
for 15 min. Chloroacetyl chloride (102 mg, 0.9 mmol, 1.5 equiv) was added in dropwise. After 15
min at 0 °C and 45 min of stirring at room temperature, the reaction mixture was poured into a
mixture of 500 mL of ice and 100 mL of hydrochloric acid. The organic phase was extracted and
washed with brine. The product was dried over sodium sulfate collected after concentrated. The
product was obtained as white solid (140 mg, 96% yield). 1H NMR (500 MHz, CDCl3) δ 8.13 (m,
1H), 7.96 (m, 1H.), 7.82 (m, 1H), 7.56 (m, 1H), 7.40 (m, 3H), 4.73 (s, 2H), 3.93 (s, 2H).
General synthesis for SN2 coupling of alkyl thiols
The reaction was performed by dissolving the thiol (1.0 equiv) in 3 mL of DMF (deoxygenated by
bubbling N2) and adding K2CO3 (2.0 equiv). The chloroacetamide (1.2 equiv) was then added to
the reaction mixture and stirred overnight at room temperature. The reaction was diluted in EtOAc
and washed with water. The water layer was extracted three times with EtOAc, washed with brine,
dried over Na2SO4, filtered, and concentrated to give the crude product, which was purified as
indicated.
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2-{[2-(9H-flouoren-2-yl)-2-oxoethyl]}-N-[1-phenyl-3-(2,4,5-trimethylphenyl0-1H-pyrazol5yl]acetamide (216) The mixture was purified by silica column chromatography using (1:3 Ethyl
Acetate: Hexane) to give a white solid (0.017 g, 50% yield). 1H NMR (500 MHz, CDCl3) δ 8.94
(s, 1H), 8.55 (s, 1H), 8.09 (s, 1H), 7.73 (m, 3H), 7.52–7.44 (m, 8H), 7.00 (s, 1H), 6.82 (s, 1H), 3.4
(s, 2H), 3.30 (s, 2H), 2.42 (s, 3H), 2.24 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 193.4, 165.2, 152.3,
147.4, 144.5, 143.4, 140.0, 137.8, 136.1, 135.3, 133.6, 133.1, 132.7, 132.1, 130.17, 129.9, 128.3,
128.0, 127.9, 127.1, 125.2, 125.1, 121.0, 119.8, 98.7, 60.3, 53.3, 37.9, 36.7, 36.2, 20.6, 19.3;
HRMS calculated for C35H31N3O2S (M+H)+ 558.2210, found 558.2201.

2-[(2-{2-azatricyclo[9.4.0.0]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}-2-oxoethyl)sulfanyl]
-N-[1-phenyl-3-(2,4,5-trimethylphenyl)-1H-pyrazol-5-yl]acetamide (227) The mixture was
purified by silica column chromatography using (1:2 Ethyl Acetate:Hexane) to give a white solid
(0.013 g, 60% yield). 1H NMR (500 MHz, CDCl3) δ 9.57 (s, 1H), 7.52 (m, 2H), 7.42 (m, 5H),
7.23–7.25 (m, 5H), 7.01 (s, 2H), 6.85 (s, 2H), 3.40 (s, 2H), 3.30 (s, 2H), 2.88 (m, 4H), 2.45 (s,
3H), 2.22 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 168.8, 166.5, 152.3, 141.0, 139.2, 138.2, 137.7,
136.2, 135.9, 134.6, 133.3, 132.2, 130.9, 129.4, 128.1, 127.7, 127.2, 126.6, 125.5, 124.6, 99.7,
35.62, 32.1, 29.7, 28.4, 20.7, 20.5, 18.9; HRMS calculated for C36H34N4O2S (M+H)+ 587.2475,
found 587.2477.
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2-({[(naphthalen-2-yl)carbamoyl]methyl}sulfanyl)-N-[1-phenyl-3(2,4,5trimethylphenyl)1H-pyrazol-5-yl]acetamide (231) The mixture was purified by silica
column chromatography using (1:3 Ethyl Acetate: Hexane) to give a white solid (0.019 g, 50%
yield). 1H NMR (500 MHz, CDCl3) δ 9.12 (s, 1H), 8.03 (s, 1H), 7.88 (m, 1H), 7.84 (m, 1H), 7.81
(m, 1H), 7.59 (m, 1H), 7.50 (m, 2H), 7.42 (m, 6H), 7.35 (m, 1H), 7.03 (s, 1H), 6.91 (s, 1H), 3.93
(s, 2H), 3.41 (s, 2H), 2.49 (s, 3H), 2.25 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 166.7, 166.2, 152.4,
137.9, 136.3, 135.1, 134.6, 133.6, 133.1, 132.2, 130.8,130.2, 129.8, 129.7, 128.9, 128.7, 128.3,
127.7, 127.6, 127.1, 126.6, 125.2, 125.1, 121.0, 119.8, 117.0, 99.6, 36.6, 36.0, 20.6, 19.3, 19.0;
HRMS calculated for C32H30N4O2S (M+H)+ 535.2162, found 535.2157.

N-[1-phenyl-3-(2,4,5-trimethylphenyl)-1H-pyrazol-5-yl]-2-({[(3,4,5-trimethoxyphenyl)
carbamoyl]methyl}sulfanyl)acetamide (238) The mixture was purified by silica column
chromatography using (2:1 Ethyl Acetate: Hexane) to give a white solid (0.016 g, 62% yield). 1H
NMR (500 MHz, CDCl3) δ 8.67 (s, 1H), 8.35 (s, 1H), 7.53 (m, 2H), 7.50 (m, 2H), 7.40 (m, 2H),
7.04 (s, 1H), 6.85 (s, 1H), 6.80 (s, 2H), 3.78 (s, 9H), 3.41 (s, 2H), 3.27 (s, 2H), 2.46 (s, 3H), 2.25
(s, 6H);
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C NMR (125 MHz, CDCl3) δ 166.6, 153.2, 152.6, 138.0, 134.9, 133.7, 133.3, 128.3,
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124.9, 100.0, 97.6, 61.0, 56.1, 36.6, 36.0, 20.6, 19.2; HRMS calculated for C31H34N4O5S (M+H)+
575.2323, found 575.2329.

2-({[(1,3-benzothiazol-6-yl)carbamoyl]methyl}sulfanyl)-N-[1-phenyl-3-(2,4,5
trimethylphenyl)-1H-pyrazol-5-yl]acetamide (255) The mixture was purified by silica column
chromatography using (2:1 Ethyl Acetate:Hexane) to give a white solid (0.005 g, 49% yield). 1H
NMR (500 MHz, CDCl3) δ 8.91 (s, 1H), 8.57 (m, 2H), 8.45 (s, 1H), 8.04 (s, 1H), 7.55 (m, 5H),
7.39 (m, 2H), 7.01 (s, 1H), 6.88 (s, 1H), 3.47 (s, 2H), 3.36 (s, 2H), 2.47 (s, 3H), 2.25 (s, 6H); 13C
NMR (125 MHz, CDCl3) δ 167.2, 166.1, 153.9. 152.5, 150.26, 138.0, 136.4, 135.2, 133.9, 133.2,
132.5, 130.5, 129.5, 128.3, 125.2, 123.7, 119.2, 112.8, 99.6, 36.7, 36.1, 20.7, 19.2; HRMS
calculated for C29H27N5O2S2 (M+H) + 542.1679, found 542.1661.
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2-({[(adamantan-1-yl)carbamoyl]methyl}sulfanyl)-N-[1-phenyl-3(2,4,5trimethylphenyl)1H-pyrazol-5-yl]acetamide (278) The mixture was purified by silica
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column chromatography using (1:2 Ethyl Acetate: Hexane) to give a white solid (0.017 g, 57%
yield). 1H NMR (500 MHz, CDCl3) δ 9.44 (s, 1H), 7.53 (m, 2H), 7.42 (m, 2H), 7.35 (m, 2H), 7.00
(s, 1H), 6.79 (s, 1H), 3.29 (s, 2H), 2.93 (s, 2H), 2.40 (s, 3H), 2.20 (s, 6H), 1.98 (s, 3H), 1.83 (m,
6H), 1.57 (m, 6H); 13C NMR (125MHz, CDCl3) δ 167.6, 166.2, 152.4, 138.3, 136.3, 135.7, 133.9,
133.3, 132.2, 130.2, 128.0, 99.2, 41.4, 36.4, 29.5, 20.5, 19.2; HRMS calculated for C32H38N4O2S
(M+H)+ 543.2788, found 543.2789.
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N-(diphenylmethyl)-2-[({[1-phenyl-3-(2,4,5-trimethylphenyl)-1H-pyrazol-5-yl]carbamoyl}
methyl)sulfanyl]acetamide (280) The mixture was purified by silica column chromatography
using (1:4 Ethyl Acetate: Hexane) to give a white solid (0.017 g, 52% yield). 1H NMR (500 MHz,
CDCl3) δ 9.11 (s, 1H), 7.48 (m, 2H), 7.40 (m, 3H), 7.29 (m, 8H), 7.18 (m, 3H), 7.02 (m, 1H), 6.80
(s, 1H), 6.08 (d, 1H, J = 8.5 Hz), 3.26 (s, 2H), 3.13 (s, 2H), 2.48 (s, 3H), 2.25 (s, 6H); 13C NMR
(125 MHz, CDCl3) δ 168.0, 166.2, 152.3, 140.7, 138.0, 136.4, 135.6, 129.5, 128.7, 127.2, 125.3,
124.8, 99.6, 57.5, 35.7, 35.1, 20.7, 19.1; HRMS calculated for C35H34N4O2S (M+H)+ 575.2475,
found 575.2472.
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N-[(4-fluorophenyl)methyl]-2-[({[1-phenyl-3-(2,4,5-trimethylphenyl)-1Hpyrazol5yl]carbamoyl}methyl)sulfanyl]acetamide (286) The mixture was purified by silica
column chromatography using (1:3 Ethyl Acetate: Hexane) to give a white solid (0.014 g, 54%
yield). 1H NMR (500 MHz, CDCl3) δ 9.05 (s, 1H), 7.55 (m, 2H), 7.47 (m, 2H), 7.38 (m, 2H), 7.19
(m, 2H), 6.99 (m, 3H), 6.83 (m ,1H), 6.47 (s,1H), 4.30 (m, 1H), 3.38 (s, 2H), 3.13 (s, 2H), 2.49 (s,
3H), 2.23 (s, 6H); 13C NMR (125MHz, CDCl3) δ 168.4, 166.1, 152.5, 138.0, 136.5, 135.5, 133.4,
132.4, 130.4, 129.7, 128.4, 125.1, 115.8, 99.5, 43.2, 36.2, 35.6, 20.7, 19.5, 19.2; HRMS calculated
for C29H29N4O2FS (M+H)+ 517.2068, found 517.2068.
Synthetic procedures for aromatic sulfide derivatives
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5H-[1,2,4]triazino[5,6-b]indole-3-thiol (15)21 In a round-bottom flask, isatin (200 mg, 1.36
mmol, 1.0 equiv) and potassium carbonate were dissolved 5 mL of water. (124 mg, 1.36 mmol,
1.0 equiv) of thiosemicarbazide was added to a solution. The reaction was reflux for 16 h. The
reaction mixture was acidified by using 0.5 mL acetic acid. The yellow precipitate was afforded
and washed with water and acetic acid (12:1). The yellow solid was triturated with hot DMF. The
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product was filtered and dried under high vacuum to give a yellow solid (119 mg, 0.59 mmol, 43%
yield). 1H NMR (500 MHz, DMSO-D6) δ 7.99 (d, 1H, J = 8.0 Hz), 7.94 (s, 1H), 7.61 (t, 1H, J =
8.0 Hz), 7.42 (d, 1H, J = 8.9 Hz), 7.33 (t, 1H, J = 8.0 Hz); 13C NMR (125 MHz, CDCl3) δ 113.4,
118.4, 122.3, 123.5, 132.3, 135.9, 143.6, 149.6, 179.6; HRMS calculated for C9H6N4S (M+H)+
203.0389, found 203.0386.

2-((5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(1-phenyl-3-(2,4,5trimethylphenyl)1Hpyrazol-5-yl)acetamide (541) The reaction was performed by dissolving the
thiol 15 (10 mg, 0.049 mmol, 1.0 equiv) in 3 mL of methanol and adding triethyl amine (1.5 equiv).
The chloroacetamide (1.0 equiv) was added to the reaction mixture and stirred overnight at room
temperature. The reaction mixture was filtered and washed with methanol. The product was
collected after high vacuum as a yellow powder (15 mg, 0.028 mmol, 58% yield). 1H NMR (500
MHz, CDCl3) δ 10.37 (s, 1H), 8.29 (d, 1H, J = 10.8), 7.66 (m, 1H), 7.56 (m, 3H), 7.41 (m, 1H),
7.32 (m, 4H), 7.19 (m, 1H), 6.96 (s, 1H), 6.64 (s, 1H), 4.19 (s, 2H), 2.39 (s, 3H), 2.15 (s, 6H); 13C
NMR (500 MHz, DMSO-D6) δ 18.6, 20.3, 39.5, 102.0, 112.5, 116.7, 121.1, 122.7, 123.9, 126.8,
128.7, 129.5, 130.8, 140.3, 146.4, 150.9, 166.0, 166.9; HRMS calculated for C29H25N7OS (M+H)+
520.1919, found 520.1914.
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5-bromonicotinoyl chloride (16) 5-Bromonicotinic acid (100 mg, 0.5 mmol, 1.0 equiv) was
dissolved in 3 mL of 1,2-dichloroethane. Thionyl chloride (0.11 mL, 1.5 mmol, 3.0 equiv) was
added to the reaction mixture followed by one drop of DMF. The reaction was heated and reflux
for overnight. The reaction was stopped and cooled to room temperature. The excess thionyl
chloride was removed under reduced pressure to give a carbonyl chloride that was used for the
next step without further purification.
N
Br
O
NH
HS

17

5-bromo-N-(3-mercaptophenyl)nicotinamide (17)22 3-Aminothiophenol (46 mg, 0.37 mmol,
1.0 equiv) was dissolved in 5 mL of dichloromethane. The carbonyl chloride 16 (82 mg, 0.37
mmol, 1.0 equiv) and pyridine (0.044 mL, 0.55 mmol, 1.5 equiv) were added to the solution at –
10 ºC and the reaction was stirred overnight at room temperature. The reaction mixture was washed
with 10 mL of 1M HCl and the solvent was removed under reduced pressure. The solid was
dissolved in 2:1 methanol and water. Potassium carbonate (51 mg, 0.37 mmol, 1.0 equiv) was
added and the reaction mixture was stirred for one hour at room temperature. The crude mixture
was acidified to pH = 1 by using 1M HCl. The methanol was removed under reduced pressure and
the aqueous layer was extracted by dichloromethane. The organic layer was washed with brine,
dried over Na2SO4, filtered, and concentrated. The mixture was purified by silica column
chromatography using (2:1 Ethyl Acetate: Hexane) to give a white solid (40 mg, 0.129 mmol, 35%
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yield). 1H NMR (500 MHz, CDCl3) δ 8.96 (s, 1H), 8.83 (s, 1H), 8.31 (s, 1H), 7.99 (s, 1H), 7.65 (s,
1H), 7.31 (d, 1H, J = 8.6), 7.26 (m, 1H), 7.07 (d, 1H, J = 8.6), 3.53 (s, 1H); 13C NMR (125 MHz,
CDCl3) δ 117.2, 120.3, 124.8, 129.6, 132.4, 137.8. 139.3, 147.5, 153.2, 162.5.

5-bromo-N-(3-((2-oxo-2-((1-phenyl-3-(2,4,5-trimethylphenyl)-1H-pyrazol5yl)amino)ethyl)thio)phenyl)nicotinamide (551). The thiol 17 (22 mg, 0.071mmol, 1.0 equiv)
was dissolved in 3 mL of DMF (deoxygenated by bubbling N2) and K2CO3 (22 mg, 0.163 mmol,
2.3 equiv) was added. The chloroacetamide (25 mg, 0.071 mmol, 1.0 equiv) was added to the
reaction mixture and stirred overnight at 110 ºC. The reaction was diluted in EtOAc and washed
with water. The organic layer was washed with brine, dried over Na2SO4, filtered and
concentrated. The purification was done by using (2:1 Ethyl acetate: Hexane) to give (23 mg, 0.037
mmol, 51% yield). 1H NMR (500 MHz, CDCl3) δ 8.98 (s, 1H), 8.90 (s, 1H), 8.74 (s, 1H), 8.26 (s,
2H), 7.46 (m, 2H), 7.32–7.23 (m, 5H), 6.93 (m, 2H), 6.88 (s, 1H), 6.80 (s, 1H), 3.73 (s, 2H), 2.37
(s, 3H), 2.13 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 19.2, 19.5, 20.7, 37.2, 98.4, 118.7, 118.9,
124.6, 128.4, 130.0, 130.3, 133.2, 137.8, 138.1, 146.0, 152.6, 153.7, 162.6, 164.7; LRMS
calculated for C32H29BrN5O2S (M+2H)2+ 313.6, found 313.9.
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CHAPTER 2
SYNTHESIS AND CHARACTERIZATION OF GREEN LIGHT EMITTING SPIROLACTAM
RHODAMINE BASED PHOTOSWITCH FOR USE IN A 3D LIGHT PAD

Fluorescence emission from small organic photoswitch molecules can be used to generate
images and animations in a volumetric three-dimensional light photoactivatable dye display (3D
Light PAD). These high-resolution 3D light structures can be formed by projecting two light beams
with UV and visible wavelengths simultaneously through a solution of fluorescent photoswitches.
Our group has successfully used photoactivatable red-emitting N-phenyl spirolactam rhodamine B
derivatives in a first-generation 3D Light PAD.51 To move towards our goal of developing a truecolor 3D volumetric display, we have synthesized fluorescent photoswitches with green emission.
This chapter will highlight the design and synthesis of a green emitting spirolactam rhodamines,
as well as the characterization of their photochemical properties.
2.1. Introduction
2.1.1 Volumetric 3D Displays
Volumetric 3D displays may well be used for medical imaging, engineering, education,
and alternative areas due to explicit attractive properties. 51 Compared with traditional 3D displays
like stereoscopic displays, volumetric 3D displays fully incorporate physical depth cues that
account for some physical factors, like the eyes’ activities upon focusing at completely different
distances and angles, motion optical phenomenon distinction, and binocular inequality that is
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caused by the space of left eye and right eye.52 Additionally, volumetric 3D displays are often
characterized into swept-volume displays, which implies they will be used for high-speed image
generation and rotating screen-based image generation, and static volume displays that embody
active-matrix displays and beam-addressable displays.53 However, there are several challenges for
final image generation, together with advanced fabrication, moving components, high-speed
projectors, and appropriate optical device powers, which will limit the wide use of this
technology.54
Our group has used innovative chemistry to enable a volumetric 3D digital light
photoactivatable dye display (3D Light PAD) and has shown that it is a good methodology for 3D
image generation. There are two necessary factors for this system, one could be a special category
of photoactivatable molecules, and the other is digital light processing (DLP) technology to get
structured light in three dimensions.55
Photoactivatable molecules with a specific set of optical properties: a non-fluorescence
state, a visible fluorescent state and simple photochemical change from off-state to on-state.38 Our
group used spirolactam rhodamine photoswitches as the chemical agent in the 3D Light PAD.
Rhodamine dyes and fluorogenic compounds are often used as laser dyes, tracer agents, and
biological probes.56
N-aryl spirolactam rhodamine derivatives with fluorinated aminoalkyl groups (SRCF3)
that have green (518 nm) emission wavelengths were prepared so that we can better understand
the design principles of spirolactam rhodamine photoswitches and ultimately generate
photoswitches of different colors that would be suitable for use in a multi-color 3D Light PAD.
Our group reported the synthesis of these derivatives. This includes a new procedure of preparing
fluorinated spirolactam rhodamine derivatives and a method to measure the kinetics and quantum
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yields of the photoswitching process. The information gathered was used to provide a preliminary
demonstration of 3D voxel formation using a green-emitting spirolactam rhodamine photoswitch
in a 3D Light PAD display for a multi-color volumetric 3D display. Also, the fluorinated
spirolactam rhodamines containing trifluoromethyl amino groups as a photoswitch with green
fluorescence emission at 518 nm were identified.
The research team under Professor Lippert’s direction collected exciting preliminary
results that display the use of innovative chemistry for 3D image generation.57 The 3D light
structures can be formed by projecting the dual-wavelength beams into a solution of a fluorescent
photoswitch. They synthesized and measured the photophysical properties of a range of N-aryl
spirolactam rhodamine B (SRB) photoswitches with red (585 nm) emission wavelengths. The 3D
light structures can be formed by projecting the dual-wavelength beams into a solution of a
fluorescent photoswitch. Following this initial report, we successfully synthesized a significant
number of new fluorescent photoswitches and measured their photoswitching properties. 58
A 3D Light PAD emits light at specific points in 3D space only at the intersection of
ultraviolet (UV) and visible patterned light provided by commercially available Digital Light
Processing (DLP) projectors using fluorescent photoswitches dissolved within a solvent as it
shown in Figure 2.1A. The development of a scalable and true-color 3D monitor requires a greater
understanding of the fundamental molecular information of photoswitch chemistry. Spirolactam
rhodamines are photoswitches with properties suitable for use in a 3D Light PAD, such as (1)
balance between photoactivation and thermal relaxation rates, (2) a fluorescent on-state, (3)
photoswitching caused by non-visible ultraviolet radiation. Under normal conditions, these
photoswitches show a colorless and non-fluorescent "closed" conformation (1a). When exposed
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to UV light, the spirolactam ring opens, resulting in a completely conjugated "open" shape (2b)
that fluoresces when excited with visible light (Figure 2.1 B).

Figure 2.1. (A) Diagram and function of the fluorescent photoswitch in a 3D Light PAD. (B) 3D
images generated by a 3D Light PAD.

The photochromic properties of N-phenyl spirolactam rhodamines, and subsequent
experiments on the process showed significant effects from solvent and pressure. This was first
identified by Knauer and Gleiter.59 When it was discovered that the photoswitching properties of
spirolactam rhodamines made them suitable for superresolution microscopy, derivatives suitable
for this technique were prepared and tested. This research yielded a variety of N-substituted
spirolactam rhodamines with emission ranging from green to far-red and water solubility.
2.2 Results and Discussion:
Our group (Bo Li, Uroob Haris, Andrew Nakatsuka, and I) worked on three aims:
1.

Develop rationally designed red fluorescent photoswitch derivatives

with better water solubility and photoswitching kinetics.
2.

Synthesize a green fluorescent photoswitch and characterize it.

3.

Measure the kinetics of the photoswitching process.
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Figure 2.2. General structure of red and green dye.
Green emitting photoswitches with trifluoromethyl substituents on the rhodamine
nitrogens are established, but their turn-on rates are slow and turn-off rates are fast, respectively.60
Green-emitting derivatives were prepared as shown in Scheme 2.1 below, after formation of
fluorescein ditriflates from fluorescein, followed by a palladium cross-coupling between
fluorescein triflates and 2,2,2-trifluoroethylamine.61 The reaction was done by using tris
(dibenzylideneacetone)dipalladium(0)

(Pd2dba3)

as

a

catalyst

with

biaryl

ligand

2-

Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl XPhos in dioxane. POCl3-mediated acid
chloride formation was accompanied by acyl substitution with aniline or alkyl amine to produce
diverse amination substrates as it show in Table 2.1.62

Scheme 2.1. Synthesis of Green Spirolactam Rhodamine (SRCF3).
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Figure 2.3. List of compounds prepared.
Figure 2.3 shows the green spirolactam rhodamine with various amines. Starting with
aniline 23 as the parent compound, analogues were prepared by adding electron-withdrawing
groups to various amines such as (21, 22, 24, 26, 27, 29, 31 and 32). On other hand, we also
synthesized the green spirolactam rhodamine with sterically hindered amines groups such as (25
and 30). Finally, the large conjugated system in the coumarinic ring was successfully synthesized
as compound 28.
As a preliminary demonstration of 3D voxel formation, we used a 254 nm excitation source
and the 2-fluoro SRCF3 in dichloromethane. In a 2.5 cm x 2.5 cm x 5 cm cuvette, the photoswitch
was dissolved at 5 M in dichloromethane with 7.2 M triethylamine. A mask was made to fit over
a 254 nm TLC lamp, allowing a line of UV light to project up from the TLC lamp into the cuvette
(Figure 2.3A). A LightCrafter 4500 projector was used to project a square of blue light from the
side. A voxel of green light can be seen using this configuration (Figure 2.3 B), demonstrating the
feasibility of using green SRCF3 photoswitches in a 3D Light PAD. Unfortunately,
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photoactivation was only effective at 254 nm, so patterning could not be accomplished using the
commercially available WinTech 4500 UV projector (as used in our previous work), which has a
385 nm LED.

Figure 2.4. (A) Schematic and (B) photograph of the 3D voxel formation design, which includes
a 254 nm TLC lamp, the blue LED of a LightCrafter 4500 projector, and a cuvette loaded with 5
mM 22 and 7.2 M triethylamine.

2.3 Conclusion
The synthesis of rhodamine derivatives was done successfully with fluorinated aminoalkyl
groups (SRCF3) that have green (518 nm) emission wavelengths. This includes a new procedure
of preparing fluorinated spirolactam rhodamine derivatives so that we can better understand the
design principles of spirolactam rhodamine photoswitches and ultimately generate photoswitches
of different colors that would be suitable for use in a 3D Light PAD.
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2.4 Experimental Section

3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-3',6'-diyl bis(trifluoromethanesulfonate) (18)
Fluoresceinin (1020 mg, 3.1 mmol, 1 equiv) was dissolved in 30 mL of dichloromethane.
Trifluoromethanesulfonic

Anhydride

(2215

mg,

6.2

mmol,

2

equiv)

and

N,N-

Diisopropylethylamine (1.6 mL, 9.3 mmol, 3 equiv) added to the reaction mixture and run for
overnight at room temperature. The reaction mixture washed with 15 mL of 1M HCl and 15 mL
of NaHCO3. The mixture extracted with CH2Cl2, dried with Na2SO4, filtered, and concentrated.
Purification done by using silica column chromatography (20:1 DCM/ CH3OH) affording the
product as a light yellow solid (3.56 g, 71% yield). 1H NMR (500 MHz, CDCl3)  8.05 (d, J = 7.0
Hz, 1H), 7.737.69 (m, 2H), 7.29 (s, 2H), 7.19 (d, J = 6.6 Hz, 1H), 7.016.97 (m, 4H); 13C NMR
(125 MHz, CDCl3)  168.7, 152.1, 151.4, 150.2, 131.0, 130.0, 125.8, 123.7, 119.3, 117.7, 110.7,
80.1.

3',6'-bis((2,2,2-trifluoroethyl)amino)-3H-spiro[isobenzofuran-1,9'-xanthen]-3-one

(19)

Fluorescein ditriflate (1 g, 1.68 mmol, 1 equiv), tris (dibenzylideneacetone) dipalladium (155 mg,
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0.17 mmol, 0.1 equiv), 2-Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (238 mg, 2.5
mmol, 0.3 equiv) and cesium carbonate (1.5g, 4.6 mmol, 2.8 equiv), were added to a pressure
flask. The flask was evacuated and backfilled with N 2 three times. Then 8 mL of anhydrous
dioxane was added to the flask and let it run for 20 minute at room temperature.
2,2,2Trifluoroethylamine (1.3 mL, 4 mmol, 2.4 equiv) was added to the pressure flask and sealed
immediately. The mixture was stirred for 20 minute at room tempreature. Then the mixture was
heated to 100 °C and stirred for 16 h. The reaction was concentrated and the crude was purified
by the silica column chromatography (4:1 DCM/isopropanol) to provide dark red crystal (600 mg,
72%). 1H NMR (500 MHz, CDCl3)  7.99 (m, 1H), 7.65 (m, 1H), 7.59 (m, 1H), 7.17 (d, 1H), 6.58
(s, 2H), 6.51 (m, 2H), 6.36 (t, J = 8.3 Hz, 2H), 4.23 (s, 2H), 3.78 (m, 4H); 13C NMR (125 MHz,
CDCl3)  167.7, 154.8, 154.0, 133.3, 131.9, 130.6, 128.7, 123.9, 108.7, 98.1, 69.3, 44.6, 37.9,
30.0, 14.9, 12.6; HRMS calculated for C24H16N2O3F6 [M+H]+ 495.1121, found 495.1119.

CF3 aniline (20). Rhodamine-CF3 (50 mg, 0.1 mmol, 1 equiv) was dissolved with 8 mL of DCM.
Aniline (0.028 mL, 0.3 mmol, 3 equiv) was added to the reaction mixture. The reaction was cooled
in ice bath before adding phosphoryl chloride (0.012 mL, 0.12 mmol, 1.2 equiv). The reaction was
run for 20 min at 0 °C and reflux for overnight. The reaction mixture was washed with 10 mL of
1 M HCl and 10 mL of 1M of NaOH. The extraction was done with DCM, washed with brine,
dried with Na2SO4, filtered, and concentrated. Purification done by using silica column
chromatography (1:1 ACOEt/ Hexane) affording the product 20 as a red solid (1.59 g, 64% yield).
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H NMR (500 MHz, CDCl3)

1

7.99 (m, 1H), 7.65 (m, 1H), 7.59 (m, 1H), 7.17 (d, 1H), 6.58 (s,

2H), 6.51 (m, 2H), 6.36 (t, J = 8.3 Hz, 2H), 4.23 (s, 2H), 3.78 (m, 4H);

13

C NMR (125 MHz,

CDCl3)  167.7, 154.8, 154.0, 133.3, 131.9, 130.6, 128.7, 123.9, 108.7, 98.1, 69.3, 44.6, 37.9,
30.0, 14.9, 12.6; HRMS calculated for C24H16N2O3F6 [M+H]+ 495.1121, found 495.1119.

2-phenyl-3',6'-bis((2,2,2-trifluoroethyl)amino)spiro[isoindoline-1,9'-xanthen]-3-one

(23)

Rhodamine-CF3 (305 mg, 0.607 mmol, 1.0 equiv) and aniline (0.17 mL, 1.82 mmol, 3.0 equiv)
were dissolved in dichloromethane (10 mL). The mixture was cooled to 0 °C, then POCl 3 (0.07
mL, 0.73 mmol, 1.2 equiv) was added dropwise. The reaction mixture was allowed to stir at 0 °C
for 15 min and then heated to 45 °C for 20 h. The mixture was diluted with 10 mL dichloromethane
and then washed with 1 M HCl (3 x 10 mL), 1 M NaOH (3 x 10 mL) and brine. The organic layer
was collected, dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude
product was purified by silica gel chromatography with ethyl acetate:hexane (1:4) as the eluent,
affording the product 23 as a white solid (141.2 mg, 40% yield). The compound can be additionally
purified by recrystallization from ethyl acetate: hexanes (1:2). 1H NMR (500 MHz, CDCl3)  8.01
(d, J = 7.1 Hz, 1H), 7.54–7.50 (m, 2H), 7.147.08 (m, 4H), 6.54 (d, J = 8.0 Hz, 4H), 6.30 (d, J
= 8.6 Hz, 4H), 3.73 (q, J = 6.6 Hz, 4H). 13C NMR (125 MHz, CDCl3)  167.6, 152.7, 147.0, 135.9,
132.9, 131.3, 129.1, 127.3, 126.2, 123.7, 110.3, 99.3, 67.1, 45.9, 29.7; HRMS calculated for
C30H21N3O2F6 [M+H]+ 570.1533, found 570.1531.
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2-(2-fluorophenyl)-3',6'-bis((2,2,2-trifluoroethyl)amino)spiro[isoindoline-1,9'-xanthen]-one
(22) Rhodamine-CF3 (311 mg, 0.607 mmol, 1.0 equiv) and 2-fluoro aniline (0.18 mL, 1.83 mmol,
2.9 equiv) were dissolved in dichloromethane (10 mL). The mixture was cooled to 0 °C, then
POCl3 (0.07 mL, 0.73 mmol, 1.2 equiv) was added dropwise. The reaction mixture was allowed
to stir at 0 °C for 15 min and then heated to 45 °C for 20 h. The mixture was diluted with 10 mL
dichloromethane and then washed with 1 M HCl (3 x 10 mL), 1 M NaOH (3 x 10 mL) and brine.
The organic layer was collected, dried over Na 2SO4, filtered, and concentrated under reduced
pressure. The crude product was purified by silica gel chromatography with ethyl acetate:hexane
(1:2) as the eluent, affording the product as a white solid (221.4 mg, 62% yield). The compound
22 can be additionally purified by recrystallization from ethyl acetate: hexanes (1:2). 1H NMR
(500 MHz, CDCl3)  8.01−8.05 (m, 1H), 7.54 (t, J = 4.9 Hz, 2H), 7.12−7.16 (m, 2H), 6.77 (t, J
= 10.3 Hz, 1H), 6.61 (d, J = 8.6 Hz, 2H), 6.57 (m, 2H), 6.31 (dd, J = 2.3, 8.6 Hz, 4H), 4.12 (t, J
= 8.8 Hz, 2H), 3.73 (p, J = 13.3 Hz, 4H); 13C NMR (125 MHz, CDCl3)  166.8, 159.6, 152.9, 152.6,
147.6, 133.1, 130.9, 129.8, 129.5, 129.0, 128.7, 125.9, 124.0, 123.9, 123.7, 116.4, 116.2, 110.2,
109.6, 99.0, 66.9, 53.4, 45.9, 45.6, 29.7; HRMS calculated for C30H20N3O2F7 [M+H]+ 588.15,
found 588.15.
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2-(2,6-diisopropylphenyl)-3',6'-bis((2,2,2-trifluoroethyl)amino)spiro[isoindoline1,9'xanthen]-3-one (30) Rhodamine-CF3 (152 mg, 0.307 mmol, 1.0 equiv) and 2,6-diisopropyl
aniline (0.16 g, 0.906 mmol, 2.9 equiv) were dissolved in dichloromethane (10 mL). The mixture
was cooled to 0 °C, then POCl3 (0.04 mL, 0.36 mmol, 1.2 equiv) was added dropwise. The reaction
mixture was allowed to stir at 0 °C for 15 min and then heated to 45 °C for 20 h. The mixture was
diluted with 10 mL dichloromethane and then washed with 1 M HCl (3 x 10 mL), 1 M NaOH (3
x 10 mL) and brine. The organic layer was collected, dried over Na 2SO4, filtered, and concentrated
under reduced pressure. The crude product was purified by silica gel chromatography with ethyl
acetate: hexane (1:3) as the eluent, affording the product 30 as a white solid (120.1mg, 62% yield).
The compound can be additionally purified by recrystallization from ethyl acetate:hexanes (1:2).
H NMR (500 MHz, CDCl3)  8.06 (d, J = 6.9 Hz, 1H), 7.63 (m, 1H), 7.03 (d, J = 7.6 Hz, 2H),

1

6.97 (m, 2H), 6.82 (m, 2H), 6.59–6.57 (m, 1H), 6.33 (d, J = 6.8 Hz, 2H), 6.26 (d, J = 5.4 Hz, 2H),
3.72 (m, 4H), 2.30 (m, 2H), 1.16 (s, 2H), 0.88 (d, J = 6.9 Hz, 6H), 0.41 (d, J = 6.3 Hz, 6H); 13C
NMR (125 MHz, CDCl3)  167.6, 157.0, 150.3, 133.8, 130.3, 129.7, 127.4, 123.6, 123.2, 112.0,
110.3, 100.2, 70.0, 45.4, 28.6, 21.4; HRMS calculated for C36H33N3O2F6 [M+H]+ 654.2550, found
654.2548.
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2-(3-chlorophenyl)-3',6'-bis((2,2,2-trifluoroethyl)amino)spiro[isoindoline-1,9'-xanthen]-3one (17). Rhodamine-CF3 (172 mg, 0.347 mmol, 1.0 equiv) and 3-chloro aniline (0.10 mL, 0.86
mmol, 2.5 equiv) were dissolved in dichloromethane (10 mL). The mixture was cooled to 0 °C,
then POCl3 (0.04 mL, 0.34 mmol, 1.2 equiv) was added dropwise. The reaction mixture was
allowed to stir at 0 °C for 15 min and then heated to 45 °C for 20 h. The mixture was diluted with
10 mL dichloromethane and then washed with 1 M HCl (3 x 10 mL), 1 M NaOH (3 x 10 mL) and
brine. The organic layer was collected, dried over Na2SO4, filtered, and concentrated under
reduced pressure. The crude product was purified by silica gel chromatography with ethyl acetate:
hexane (1:2) as the eluent, affording the product 31 as a white solid (117 mg, 68% yield). The
compound can be additionally purified by recrystallization from ethyl acetate: hexanes (1:2). 1H
NMR (500 MHz, CDCl3) 8.00 (d, J = 6.8 Hz, 1H), 7.54–7.50 (m, 2H), 7.117.02 (m, 3H), 6.81 (s,
1H), 6.60 (q, J = 8.3 Hz, 3H), 6.33 (d, J = 8.2 Hz, 4H), 4.1 (m, 2H), 3.75 (q, J = 6.6 Hz, 4H). 13C
NMR (125 MHz, CDCl3) 167.3, 147.6, 137.6, 134.1, 133.2, 130.6, 130.1, 129.7, 128.9, 126.7,
125.8, 124.8, 110.6, 109.7, 99.0, 67.2, 45.9. HRMS calculated for C30H20N3O2F6Cl [M+H]+
604.1221, found 604.1221.
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APPENDIX I
1

H AND 13C NMR SPECTRA
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Figure A-1. 1H NMR spectrum (400 MHz, CDCl3) of 2.
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Figure A-2. 13C NMR spectrum (100 MHz, CDCl3) of 2.
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Figure A-3. 1H NMR spectrum (400 MHz, CDCl3) of 3.
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Figure A-4. 13C NMR spectrum (125 MHz, CDCl3) of 3.
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Figure A-5. 1H NMR spectrum (400 MHz, CDCl3) of 4.
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Figure A-6. 13C NMR spectrum (125 MHz, CDCl3) of 4.
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Figure A-7. 1H NMR spectrum (400 MHz, CDCl3) of 5.
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Figure A-8. 13C NMR spectrum (125 MHz, CDCl3) of 5.
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Figure A-9. 1H NMR spectrum (400 MHz, CDCl3) of 6.
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Figure A-10. 13C NMR spectrum (125 MHz, CDCl3) of 6.
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Figure A-11. 1H NMR spectrum (400 MHz, CDCl3) of 7.
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Figure A-12. 1H NMR spectrum (400 MHz, CDCl3) of 8.
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Figure A-13. 1H NMR spectrum (400 MHz, CDCl3) of 9.
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Figure A-14. 1H NMR spectrum (400 MHz, CDCl3) of 10.
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Figure A-15. 1H NMR spectrum (400 MHz, CDCl3) of 11.
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Figure A-16. 1H NMR spectrum (400 MHz, CDCl3) of 12.
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Figure A-17. 1H NMR spectrum (400 MHz, CDCl3) of 13.
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Figure A-18. 1H NMR spectrum (400 MHz, CDCl3) of 14.
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Figure A-19. 1H NMR spectrum (400 MHz, CDCl3) of 216.
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Figure A-20. 13C NMR spectrum (125 MHz, CDCl3) of 216.

81

Figure A-21. 1H NMR spectrum (400 MHz, CDCl3) of 227.
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Figure A-22. 13C NMR spectrum (125 MHz, CDCl3) of 227.
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Figure A-23. 1H NMR spectrum (400 MHz, CDCl3) of 231.
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Figure A-24. 13C NMR spectrum (125 MHz, CDCl3) of 231.

85

Figure A-25. 1H NMR spectrum (400 MHz, CDCl3) of 238.
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Figure A-26. 13C NMR spectrum (125 MHz, CDCl3) of 238.
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Figure A-27. 1H NMR spectrum (400 MHz, CDCl3) of 255.
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Figure A-28. 13C NMR spectrum (125 MHz, CDCl3) of 255.
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Figure A-29. 1H NMR spectrum (400 MHz, CDCl3) of 278.
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Figure A-30. 13C NMR spectrum (125 MHz, CDCl3) of 278.
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Figure A-31. 1H NMR spectrum (400 MHz, CDCl3) of 280.
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Figure A-32. 13C NMR spectrum (125 MHz, CDCl3) of 280.
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Figure A-33. 1H NMR spectrum (400 MHz, CDCl3) of 286.
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Figure A-34. 13C NMR spectrum (125 MHz, CDCl3) of 286.
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Figure A-35. 1H NMR spectrum (400 MHz, CDCl3) of 15.
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Figure A-36. 13C NMR spectrum (125 MHz, CDCl3) of 15.
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Figure A-37. 1H NMR spectrum (400 MHz, CDCl3) of 541.
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Figure A-38. 13C NMR spectrum (125 MHz, CDCl3) of 541.
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Figure A-39. 1H NMR spectrum (400 MHz, CDCl3) of 17.
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Figure A-40. 13C NMR spectrum (125 MHz, CDCl3) of 17.
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Figure A-41. 1H NMR spectrum (400 MHz, CDCl3) of 551.
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Figure A-42. 13C NMR spectrum (125 MHz, CDCl3) of 551.
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Figure A-43. 1H NMR spectrum (400 MHz, CDCl3) of 19.
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Figure A-44. 13C NMR spectrum (125 MHz, CDCl3) of 19.
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Figure A-45. 1H NMR spectrum (400 MHz, CDCl3) of 23.

106

Figure A-46. 13C NMR spectrum (125 MHz, CDCl3) of 23.
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Figure A-47. 1H NMR spectrum (400 MHz, CDCl3) of 22.
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Figure A-48. 13C NMR spectrum (125 MHz, CDCl3) of 23.
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Figure A-49. 1H NMR spectrum (400 MHz, CDCl3) of 30.
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Figure A-50. 13C NMR spectrum (125 MHz, CDCl3) of 30.
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Figure A-51. 1H NMR spectrum (400 MHz, CDCl3) of 31.

112

Figure A-52. 13C NMR spectrum (125 MHz, CDCl3) of 31.

113

